Seeking AlphaCodex · 实盘不做把握 8/10
北京时间·🕒 发布 22:42:32时区推断·⟳ 抓取 22:42:34·⚡ 决策 07-29 22:43:09 +35s·89.8 天前
Alnylam 将于7月30日盘前发布二季度业绩，当前仅为财报预告与一致预期摘要
这条信号只是财报日前的日历预告和市场一致预期汇总，没有披露实际业绩、指引修正或超预期增量。
📄 原文Seeking Alpha↗ 原文
Alnylam Pharmaceuticals Q2 2026 Earnings Preview
- Alnylam Pharmaceuticals (ALNY) is scheduled to announce Q2 earnings results on Thursday, July 30th, before market ope…
不做 Alnylam Pharmaceuticals（ALNY.US）
仅为财报预告和一致预期摘要，实际业绩尚未披露，无法判断超预期方向；当前不做，等7月30日盘前财报实数和指引后由新信号重新决策。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 medium · price-in 风险 high ↗
关键理由
- 这条信号只是财报日前的日历预告和市场一致预期汇总，没有披露实际业绩、指引修正或超预期增量。
- EPS与收入数字均为市场预期本身，不构成新的公司级盈利事实或可交易 surprise。
主要风险
- 真正可交易的信息要等7月30日盘前实际财报、指引和管理层口径披露后再重新研判。
原文全文
展开原文 · 510 字
- Alnylam Pharmaceuticals (ALNY) is scheduled to announce Q2 earnings results on Thursday, July 30th, before market open.
- The consensus EPS estimate is $2.15 (vs. $0.32 in Q2/2025) and the consensus revenue estimate is $1.32B (+70.6% Y/Y).
- Over the last 2 years, ALNY has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 3 upward revisions and 7 downward. Revenue estimates have seen 8 upward revisions and 7 downward.
- The consensus EPS estimate is $2.15 (vs. $0.32 in Q2/2025) and the consensus revenue estimate is $1.32B (+70.6% Y/Y).
- Over the last 2 years, ALNY has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 3 upward revisions and 7 downward. Revenue estimates have seen 8 upward revisions and 7 downward.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。